Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan

BACKGROUND: The therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Yu-Chin, Gau, Jyh-Pyng, Huang, Shang-Yi, Ko, Bor-Sheng, Teng, Chieh-Lin Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193980/
https://www.ncbi.nlm.nih.gov/pubmed/34123862
http://dx.doi.org/10.3389/fonc.2021.695410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193980/
https://www.ncbi.nlm.nih.gov/pubmed/34123862
http://dx.doi.org/10.3389/fonc.2021.695410

Ejemplares similares